News
MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...
Scripps News on MSN3d
FDA approves Merck’s Enflonsia to prevent RSV in infantsThe Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...
The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...
Zacks.com on MSN6d
Merck Secures FDA Nod for New RSV Antibody Enflonsia in InfantsMRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
GlobalData on MSN6d
MSD receives FDA approval for Enflonsia to prevent RSVThe approval was based on data from the pivotal Phase IIb/III CLEVER trial which assessed a single dose of the antibody.
A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.
Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...
Enflonsia is the first FDA-approved respiratory syncytial virus (RSV) preventative for infants, regardless of weight, according to the news release.
Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...
RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback